openlabel

  1. T

    Relypsa Initiates Open-Label Phase 2 Clinical Study Of RLY5016 For The Management Of

    Relypsa, Inc., announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and...
Back
Top